Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid TumorsBusiness Wire • 04/23/25
Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to TradeZacks Investment Research • 03/27/25
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025Business Wire • 03/25/25
Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business UpdatesBusiness Wire • 03/20/25
Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's CancerBusiness Wire • 02/20/25
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven CancersBusiness Wire • 01/23/25
Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in ChinaBusiness Wire • 01/14/25
Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025Business Wire • 01/13/25
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review TagZacks Investment Research • 01/02/25
Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian CancerBusiness Wire • 12/30/24
Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung CancerBusiness Wire • 12/18/24
Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx ConferenceBusiness Wire • 11/26/24
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business UpdatesBusiness Wire • 11/06/24
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian CancerBusiness Wire • 10/31/24
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual MeetingBusiness Wire • 10/17/24